ITEM 1.01- Entry Into Material Definitive Agreements

AngioSoma Agreement and Plan of Reorganization

On June 3, 2016, we entered into an Agreement and Plan of Reorganization (the “Agreement”) with AngioSoma Research, Inc., a Texas corporation, a newly formed wholly owned subsidiary of First Titan Corp. (“First Titan” or the “Company”), AngioSoma, Inc., a Nevada corporation, and the stockholders of AngioSoma, Inc.  Pursuant to the Agreement, AngioSoma Research, Inc. will merge with and into AngioSoma, Inc.  First Titan’s name will change to AngioSoma, Inc. The surviving corporation, AngioSoma Research, Inc. will be domiciled in Texas as a wholly owned subsidiary of First Titan under its new name AngioSoma, Inc. The purchase price for the acquisition consists of the issuance by First Titan of 20,000,000 shares of our Common Stock, par value $0.001 per share to the stockholders of AngioSoma, Inc.

As required by Item 9.01 of Form 8-K, within 71 days after closing of the transaction described herein, the company will prepare and file with the SEC an amendment to this Form 8-K that includes the financial statements and pro forma financial information prepared pursuant to Regulation S-X of the Securities Exchange Act for the periods specified in Rule 3.05(b)(2) or Rule 8-04(b) thereunder.

ITEM 3.02 - Unregistered Sale of Equity Securities

In connection with the acquisitions described in Item 2.01 of this Report, effective June 17, 2016, the Company will issue a total of 20,000,000 shares of First Titan Common Stock to the existing stockholders of AngioSoma, Inc.

The shares will be issued without registration in reliance on the exemption in Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D thereunder.  The Company believes the exemption is available because the offering was made solely and only to the parties to the acquisitions described in this report following comprehensive due diligence investigation without any public offering or solicitation.

ITEM 5.01 – Change in Control of Registrant

Because of the acquisition described in Item 1.01 and the issuance of Common Stock shares described in Item 3.02, there will be a change in control effective on the closing date of the transaction described in Item 1.01.  The identity of the persons who acquired control, the basis of the control, the identity of the persons from whom the control was assumed, any arrangements or understandings among members of both the former and new control groups and their associates with respect to election of directors or other matters as well as the information required by Item 403(c) of Regulation S-K are included in the Information Statement filed pursuant to Section 14(f) of the Securities Exchange Act and SEC Rule 14f-1 on June 6, 2016.

ITEM 9.01 – Financial Statements and Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.